TopNews

Roche's phase III IMmotion151 study of Tecentriq & Avastin to treat advanced/metastatic RCC meets co-primary endpoint

DTAB recommends amendment to MDR to bring in clarity on fees paid for FSC

Gireesh Babu, New Delhi

Thursday, October 1, 2026, 08:00 Hrs [IST]

The Drugs Technical Advisory Board (DTAB) has recommended amendment to the Second Schedule of the Medical Devices Rules (MDR), 2017 for fees for Free Sale Certificate (FSC) in order to avoid the prevailing ambiguity

To access the full article, please log in or subscribe.

Pharma Services

Tenders & Projects

Tenders & Enquires Pharma Projects

Corporate

Company Profile Corporate Results Corporate X-ray Pharmabiz Studies of Top Companies

US FDA Update

US FDA: ANDA US FDA: Warnings US FDA: Approved NMEs US FDA: Approved NMEs US FDA: REFUSAL

Export & Import

Drug Export Procedures Drug Units With WHO GMP Certification Pharma Export Data Import Reg. Update

Pharma Laws & Documents

Notifications Pharma Regulations Patent Laws and Amendments Patent Scan Documents New Drug Approvals Notified Prices

Labs & Govt Bodies

Govt Recognised In-House R&D Units AICTE Boards & Committees List of Indian CROs List of CROs (International) Govt & approved labs of India List of State Drugs Controllers